Immunotherapy and radiation after bladder cancer surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding radiation therapy to immunotherapy after bladder removal surgery can help prevent cancer from coming back. It's for people with advanced bladder cancer who have already started immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bladder cancer called urothelial carcinoma, including mixed types like squamous or glandular.
- You must have had your bladder removed (radical cystectomy) and lymph node removal within the last 48 weeks.
- You must be currently receiving immunotherapy called a checkpoint inhibitor after surgery.
- You must not have a neobladder (a new bladder made from intestine).
- You must not have had prior radiation to the pelvic area unless it's a different area and more than 4 weeks ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether radiation therapy can help people whose bladder cancer (specifically carcinoma in situ) did not get better with BCG treatment and who are not having their bladder removed. It aims to offer a less invasive option for controlling the cancer.
This trial tests a new online adaptive radiotherapy technique for bladder cancer that adjusts the radiation plan daily based on changes in the bladder. It aims to improve treatment accuracy and reduce side effects.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This study tests whether adding an immunotherapy drug (cemiplimab) with or without another drug (fianlimab) to radiation therapy can help treat bladder cancer that has not spread. The goal is to see if this combination could be an option for people who cannot have cisplatin chemotherapy.
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Hear when a new Urothelial Carcinoma Bladder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.